keyword
MENU ▼
Read by QxMD icon Read
search

Who ovarian cancer

keyword
https://www.readbyqxmd.com/read/29052073/laparoscopy-for-primary-cytoreduction-with-multivisceral-resections-in-advanced-ovarian-cancer-prospective-validation-the-times-they-are-a-changin
#1
Marcello Ceccaroni, Giovanni Roviglione, Francesco Bruni, Roberto Clarizia, Giacomo Ruffo, Matteo Salgarello, Michele Peiretti, Stefano Uccella
BACKGROUND: Primary cytoreduction is the mainstay of treatment for advanced ovarian cancer (AOC). We developed and prospectively evaluated an algorithm to investigate the possible role of laparoscopic primary cytoreduction (LPC) in carefully selected patients, with AOC. METHODS: From June 2007 to July 2015, all patients with stage III-IV ovarian cancer and clinical conditions allowing aggressive surgery were candidate to primary cytoreduction with the aim of achieving residual tumor (RT) = 0...
October 19, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/29050014/a-real-life-analysis-of-reproductive-outcome-after-fertility-preservation-in-female-cancer-patients
#2
Sofie Hulsbosch, Martin Koskas, Carla Tomassetti, Petra De Sutter, Hans Wildiers, Patrick Neven, Thomas D'Hooghe, Frederic Amant
BACKGROUND: Fertility preservation before or during cancer treatment in young women has become an important health issue because of delayed motherhood and improved survival rates. This study evaluates the necessity and the efficacy of fertility preservation, with a focus on actual pregnancy wish and outcome after fertility preservation and cancer treatment. PATIENTS AND METHODS: All consecutive patients who received fertility preservation in 2 university referral centers before or during cancer treatment were included...
October 20, 2017: Gynecologic and Obstetric Investigation
https://www.readbyqxmd.com/read/29045555/reproductive-potential-and-performance-of-fertility-preservation-strategies-in-brca-mutated-breast-cancer-patients
#3
M Lambertini, O Goldrat, A R Ferreira, J Dechene, H A Azim, J Desir, A Delbaere, M-D t'Kint de Roodenbeke, E de Azambuja, M Ignatiadis, I Demeestere
BackgroundPreclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility. However, limited and rather conflicting clinical data are available. This study assessed the reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.Patients and MethodsThis was a retrospective analysis of two prospective studies investigating oocyte cryopreservation and ovarian tissue cryopreservation in newly diagnosed early breast cancer patients...
October 10, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29043410/determination-of-the-absolute-oral-bioavailability-of-niraparib-by-simultaneous-administration-of-a-14-c-microtracer-and-therapeutic-dose-in-cancer-patients
#4
L van Andel, H Rosing, Z Zhang, L Hughes, V Kansra, M Sanghvi, M M Tibben, A Gebretensae, J H M Schellens, J H Beijnen
INTRODUCTION: Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The pivotal phase III clinical trial has shown improved progression-free survival in patients receiving niraparib compared with those receiving placebo...
October 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29042795/significant-association-of-the-exo1-rs851797-polymorphism-with-clinical-outcome-of-ovarian-cancer
#5
Tingyan Shi, Rong Jiang, Pan Wang, Yuan Xu, Sheng Yin, Xi Cheng, Rongyu Zang
BACKGROUND: Exonuclease 1 (EXO1), one of DNA mismatch repair pathway genes, functions in maintaining genomic stability and affects tumor progression. We hypothesized that genetic variations in EXO1 may predict clinical outcomes in epithelial ovarian cancer (EOC). METHODS: In this cohort study with 1,030 consecutive EOC patients, we genotyped four potentially functional polymorphisms in EXO1 by the Taqman assay and evaluated their associations with patients' survival...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29040190/novel-therapeutics-for-ovarian-cancer-the-11th-biennial-rivkin-center-ovarian-cancer-research-symposium
#6
Neil Johnson, John B Liao
OBJECTIVE: The aim of this study was to summarize developments in novel therapeutics for ovarian cancer presented at the Ovarian Cancer Research Symposium held at the University of Washington. METHODS: A symposium of the leaders in ovarian cancer research was convened to present and discuss current advances and future directions in ovarian cancer research. RESULTS: The fourth session was held on September 13, 2016, and focused on Novel Therapeutics for Ovarian Cancer...
October 17, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29040187/palliative-radiation-therapy-for-recurrent-ovarian-cancer-efficacy-and-predictors-of-clinical-response
#7
Ginger Jiang, Tracy Balboni, Allison Taylor, Joyce Liu, Larissa J Lee
OBJECTIVE: This study aimed to report response rates and predictors of response to palliative radiotherapy (RT) for recurrent ovarian cancer. METHODS/MATERIALS: Database review identified 64 patients with symptomatic ovarian cancer recurrence who received a total of 76 courses of RT for 103 indications from March 2003 to August 2014. Radiotherapy indications were pain (44%), bleeding (32%), obstruction (15%), and other (9%). Responses were categorized as complete, partial, or none; all response (AR) was the sum of complete and partial responses...
October 17, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29040183/the-prognostic-impact-of-the-pathological-response-to-neoadjuvant-dose-dense-therapy-for-ovarian-carcinoma
#8
Takahiro Ebata, Mayu Yunokawa, Hiroshi Yoshida, Seiko Bun, Tatsunori Shimoi, Akihiko Shimomura, Makoto Kodaira, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, Tomoyasu Kato, Kenji Tamura
OBJECTIVE: The aim of this study was to assess the use of the pathological response to neoadjuvant chemotherapy (NAC) for predicting disease prognosis in patients with advanced ovarian cancer who received neoadjuvant dose-dense weekly paclitaxel and carboplatin (dd-TC) therapy. METHODS: We retrospectively investigated patients with advanced epithelial ovarian, tubal, or peritoneal carcinoma treated at our hospital from July 2004 to October 2014. Patients received dd-TC therapy as NAC followed by interval debulking surgery (IDS)...
October 17, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29028665/gynecologic-cancer-in-hiv-infected-women-treatment-and-outcomes-in-a-multi-institutional-cohort
#9
Kimberly L Levinson, David J Riedel, Laureen S Ojalvo, Wesley Chan, Ana M Azngarita, Amanda N Fader, Anne F Rositch
OBJECTIVE: To evaluate gynecologic cancer treatments in Human Immunodeficiency Virus (HIV) infected women for adherence to National Comprehensive Cancer Network (NCCN) guidelines and to describe survival by adherence to guidelines. DESIGN: Beyond cervical cancer, there is little data on treatment and outcomes for these women. This is a retrospective cohort study of HIV infected women with gynecologic cancers. METHODS: HIV infected women with gynecologic cancers from 2000-2015 were identified at two urban, comprehensive cancer centers...
October 12, 2017: AIDS
https://www.readbyqxmd.com/read/29022485/prevalence-of-%C3%AE-iii-tubulin-tubb3-expression-in-human-normal-tissues-and-cancers
#10
Fermín Person, Waldemar Wilczak, Claudia Hube-Magg, Christoph Burdelski, Christina Möller-Koop, Ronald Simon, Mercedes Noriega, Guido Sauter, Stefan Steurer, Susanne Burdak-Rothkamm, Frank Jacobsen
Microtubules are multifunctional cytoskeletal proteins that are involved in crucial cellular roles including maintenance of cell shape, intracellular transport, meiosis, and mitosis. Class III beta-tubulin (βIII-tubulin, also known as TUBB3) is a microtubule protein, normally expressed in cells of neuronal origin. Its expression was also reported in various other tumor types, such as several types of lung cancer, ovarian cancer, and esophageal cancer. TUBB3 is of clinical relevance as overexpression has been linked to poor response to microtubule-targeting anti-cancer drugs such as taxanes...
October 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29022007/is-uterine-preservation-combined-with-bilateral-salpingo-oophorectomy-to-promote-subsequent-fertility-safe-in-infiltrative-mucinous-ovarian-cancer
#11
Sebastien Gouy, Marine Saidani, Amandine Maulard, Matthieu Faron, Slim Bach-Hamba, Enrica Bentivegna, Alexandra Leary, Patricia Pautier, Mojgan Devouassoux-Shisheboran, Catherine Genestie, Philippe Morice
According to the latest World Health Organization classification (2014), mucinous ovarian cancers should be classified histologically as being either expansile or infiltrative. Compared to other epithelial cancers, both of these mucinous patterns are diagnosed, in the main, at an early stage, although they can affect relatively young patients. The infiltrative subtype is characterized by a morphologically and clinically more aggressive disease versus the expansile form. Consequently, even in young patients who would prefer fertility sparing management, the removal of both ovaries (even for a unilateral tumor) remains a common recommendation...
November 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29021083/fertility-preserving-surgery-for-advanced-stage-ovarian-germ-cell-tumors
#12
Dimitrios Nasioudis, Melissa K Frey, Eloise Chapman-Davis, Thomas A Caputo, Kevin Holcomb
OBJECTIVE: To evaluate the prevalence and safety of uterine preservation among premenopausal women diagnosed with a malignant ovarian germ-cell tumor (MOGCT) of advanced stage (stage II-IV). MATERIALS AND METHODS: The National Cancer Database was accessed and a cohort of women aged <40years, diagnosed with a MOGCT were identified. Those with stage II-IV disease who underwent cancer-directed surgery and received chemotherapy were selected for further analysis...
October 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29020823/platinum-or-nonplatinum-in-recurrent-ovarian-cancer-that-is-the-question
#13
Andrés Poveda, Christian Marth
Although platinum-based chemotherapy continues to be the first-line option for advanced ovarian cancer and for platinum recurrences beyond 6 months, platinum rechallenge is not the best approach for some patients, such as those with residual toxicities, platinum-related hypersensitivity reactions or limited platinum-sensitivity (i.e., a platinum treatment-free interval [TFIp] of 6-12 months). Results of the MITO-8 study called into question the role of single-agent nonplatinum-based regimens in this specific subset of ovarian cancer patients...
October 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/29020821/when-nonplatinum-is-the-answer-the-role-of-trabectedin-plus-pegylated-liposomal-doxorubicin-in-recurrent-ovarian-cancer
#14
Nicoletta Colombo
Trabectedin + pegylated liposomal doxorubicin (PLD) offers a well tolerated and effective nonplatinum, nontaxane alternative for treatment of ovarian cancer patients with a treatment-free interval after platinum beyond 6 months, especially for those relapsing between 6 and 12 months and those who are not candidates to receive platinum-based therapy. Using the nonplatinum trabectedin + PLD combination gives patients time to recover from platinum-related toxicities and may restore platinum sensitivity in tumor cells...
October 11, 2017: Future Oncology
https://www.readbyqxmd.com/read/29019328/second-primary-tumors-associated-with-breast-cancer-kuwait-cancer-control-center-experience
#15
Salah Fayaz, Gerges Attia Demian, Heba El-Sayed Eissa, Sadeq Abuzalouf
OBJECTIVES: To review the clinico-epidemiologic characteristics of patients who presented with two or more primary cancers, one of which was breast cancer (BC) and to develop a follow-up program for the high risk patients. PATIENTS AND METHODS: Patients who were diagnosed with BC and one or more non breast cancer (NBC) were retrospectively reviewed. Medical files were retrieved and epidemiological as well as clinical data were analyzed. RESULTS: Sixty-two patients were retrieved...
September 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/29018838/adverse-post-operative-outcomes-in-jehovah-s-witnesses-with-gynecologic-cancer-within-30%C3%A2-days-of-surgery-a-single-institution-review-of-36-cases
#16
Laura J Moulton, Peter G Rose, Haider Mahdi
Rates of blood transfusion are reported as high as 32% in women undergoing major gynecologic cancer surgery. Therefore, care of the gynecologic oncology patient who refuses blood products, such as Jehovah's witnesses, can pose a unique challenge. The objective of this study was to determine rate of adverse post-operative outcomes within 30 days of surgery in Jehovah's witnesses with gynecologic cancer. This was a retrospective cohort study of Jehovah's witnesses undergoing laparotomy or minimally invasive surgery (MIS) for gynecologic cancer at a single institution...
November 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29017822/sub-optimal-primary-surgery-leads-to-unfavorable-immunological-changes-in-ovarian-cancer-patients
#17
Marek Nowak, Ewa Głowacka, Przemysław Lewkowicz, Małgorzata Banasik, Krzysztof Szyłło, Kinga Zimna, Katarzyna Bednarska, Magdalena Klink
Primary cytoreduction, followed by chemotherapy, is a standard treatment of patients with epithelial ovarian cancer (EOC). However, the effectiveness of this treatment depend on various elements e.g. type of operation. It is accepted that optimal surgery correlates with longer survival of patients. The other element, an efficiency of immune system after surgical intervention although important is less elucidated. The aim of this study was to establish the impact of optimal and sub-optimal operation on immunological status of EOC patients regarding also their overall survival (OS)...
October 5, 2017: Immunobiology
https://www.readbyqxmd.com/read/28993225/treatment-approach-and-prognosis-of-pediatric-and-adolescent-non-epithelial-malignant-ovarian-tumors-a-retrospective-prognosis-analysis
#18
Peili Liang, Xin Zhang, Zhenfeng Zhang, Guocai Xu, Xingsu Yu, Sijin Li, Yuanyuan Zhang, Lijuan Bian, Bingzhong Zhang
BACKGROUND: Non-epithelial malignant ovarian tumors are rare in the pediatric and adolescent population. AIM: To observe the spectrum of pathology, presentation, outcome, and risk factors for survival of pediatric non-epithelial malignant ovarian tumors in a Chinese pediatric population. METHODS: This was a retrospective study of 171 girls (median age at presentation of 14 years) diagnosed with primary malignant ovarian tumors between 1990 and 2014 at the Yat-Sen Memorial Hospital and Cancer Center of Sun Yat-sen University...
October 6, 2017: Journal of Pediatric and Adolescent Gynecology
https://www.readbyqxmd.com/read/28989919/the-efficacy-and-safety-of-pegylated-liposomal-doxorubicin-monotherapy-and-combination-therapy-with-carboplatin-in-korean-patients-with-recurrent-ovarian-fallopian-tube-or-primary-peritoneal-cancer-a-single-institution-experience
#19
Young-Jae Lee, Yong-Man Kim, Shin-Wha Lee, Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Young-Tak Kim, Joo-Hyun Nam
OBJECTIVE: This study aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) with or without carboplatin in Korean patients with recurrent ovarian cancer (ROC), fallopian tube, or primary peritoneal cancer. METHODS: This retrospective study included 52 patients with ROC, fallopian tube, or primary peritoneal cancer who received PLD (50 mg/m(2)) between 1(st) December 2014 and 31(th) July 2016. RESULTS: The mean number of chemotherapy cycles was 3...
September 2017: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/28988028/intensive-care-admissions-among-ovarian-cancer-patients-treated-with-primary-debulking-surgery-and-neoadjuvant-chemotherapy-interval-debulking-surgery
#20
Kristen Pepin, Amy Bregar, Michelle Davis, Alexander Melamed, Emily Hinchcliff, Allison Gockley, Neil Horowitz, Marcela G Del Carmen
OBJECTIVE: Admissions to intensive care units (ICU) are costly, but are necessary for some patients undergoing radical cancer surgery. When compared to primary debulking surgery (PDS), neoadjuvant chemotherapy (NACT) with interval debulking surgery, is associated with less peri-operative morbidity. In this study, we compare rates, indications and lengths of ICU stays among ovarian cancer patients admitted to the ICU within 30days of cytoreduction, either primary or interval. METHODS: A retrospective chart review was performed of patients with stage III-IV ovarian cancer who underwent surgical cytoreduction at two large academic medical centers between 2010 and 2014...
October 4, 2017: Gynecologic Oncology
keyword
keyword
100582
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"